August 2007
Elan Drug Technologies
Creating Value
General present _Aug07_Elan
CONFIDENTIAL©2007
– 2 –
EDT Pipeline growth - Patient Focus
ELAN DRUG TECHNOLOGIES - OVERVIEW
Number of patients
Number of Patients Treated Daily with Products using EDT’s Technologies
uber of Patients Treated aily
ith Products using ET’s Technologies
1.015M
2.54M
3.36M
7.69M
0
1,000,000
2,000,000
3,000,000
4,000,000
5,000,000
6,000,000
7,000,000
8,000,000
2002
2005
2006
2011
General present _Aug07_Elan
CONFIDENTIAL©2007
– 3 –
Contents
• General Overview and Introduction
• Technology Overview
– NanoCrystal® Technology
– Oral Controlled Release Technologies
• Facilities Overview
– Athlone - solid oral dosage and Sterile Vial filling capabilities
• Summary – benefit to you
General Overview and Introduction
General present _Aug07_Elan
CONFIDENTIAL©2007
– 5 –
Elan Drug Technologies – Helping You Bring
Products to the Market
We Have
•
Unrivalled expertise in drug formulation, development, scale-up and manufacture
•
Suite of commercially launched, proprietary, technology-driven solutions
•
NanoCrystal® Technology for poorly water soluble compounds - four products
commercially launched with US$1.5B+ annual sales
•
Customised oral drug technologies – delayed release, extended release, pulsatile
release, chrono-timed delivery – all commercially launched
•
More than 70 products in various stages of development from feasibility through to
Phase 3.
•
A proud track record of innovation and expertise in drug optimization – in excess of
thirty products launched in 39 year history.
•
Successful collaborations with more than 30 of the world’s leading pharmaceutical
companies
GENERAL OVERVIEW & INTRODUCTION
Helping Bring Products to Market
Helping Bring Products to Market
General present _Aug07_Elan
CONFIDENTIAL©2007
– 6 –
Elan Drug Technologies – The Benefits to you
Strong Patent Estate
•
1,400 + patent estate
•
Key NanoCrystal® Technology patents
•
NanoCrystal® Technology plays in the critical <400nm crystalline particle size space